



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Saragovi, et al.  
SERIAL NUMBER: 10/600,623  
FILING DATE: June 20, 2003  
FOR: COMPOUND TARGETED FOR SPECIFIC CELLS WITH  
REDUCED SYSTEMIC TOXICITY  
GROUP ART UNIT: 1642  
EXAMINER: Brandon J. Fetterolf

March 17, 2005  
Boston, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Sir:

This paper is in response to the Restriction Requirement dated November 17, 2004 for the above-referenced patent application.

Applicants hereby elect Group III, claim 30, as specifically drawn to a method for bypassing resistance of tumor cells by p-glycoprotein pump (PGP), classified in class 424, subclass 178.1 without traverse.

The Examiner further requests that the Applicants choose one "therapeutic" agent from those listed in claim 1 or 5. Applicants respectfully choose the chemotherapeutic agent as the therapeutic agent.

Applicants reserve the right to prosecute the non-elected claims in subsequent continuation and/or divisional applications.

Applicants further request a petition for a three-month (3) extension of time under 37 C.F.R. 1.17(a)(3). With the extension the Response to the Restriction Requirement is timely due on or before March 17, 2005. The Commissioner is hereby authorized to charge the petition fee (\$510.00), to Deposit Account No. 50-3431, Attorney Reference No. OGIL-002 US), formerly 62950-010310. A duplicate copy of this Response is enclosed. Applicant is a small entity.

Respectfully submitted,

 3/17/05

James F. Ewing, Reg. No. 52,875  
Attorney for Applicants  
Customer No.: 48329  
Foley & Lardner LLP  
111 Huntington Avenue  
Boston, Massachusetts 02199  
Tel: (617) 342-4000  
Fax: (617) 342-4001

#153562 v1